Does DIO1 rs2235544 affect thyroid hormone metabolism and low free T3 relevance?

The DIO1 rs2235544 polymorphism is a key genetic regulator of peripheral thyroid hormone metabolism, altering how thyroxine (T4) is converted to active triiodothyronine (T3) and how inactive reverse T3 (rT3) is cleared.

Thyroid metabolism and clinical impact

• Genetic variations: The minor C allele increases DIO1 expression and activity, promoting efficient T4-to-T3 conversion. This results in higher free T3 (fT3), an increased fT3/fT4 ratio, and lower rT3. Conversely, the major A allele reduces deiodinase activity, leading to lower fT3 and higher rT3.
• Disease and dosing risk: These metabolic differences shift clinical risk. Individuals with the AC genotype have an approximate 3-fold increased risk of hypothyroidism, while the CC genotype is protective. Furthermore, the rs2235544 genotype (CC vs. AA) significantly influences therapeutic levothyroxine (LT4) dosing requirements.

Clinical relevance for low T3

• Therapeutic personalization: In patients with below-optimal fT3, assessing rs2235544 status helps explain a poor peripheral conversion phenotype. Modeling indicates that low-activity AA genotype carriers may achieve better hormone balance on T4/T3 combination therapy, whereas CC carriers efficiently convert T4 monotherapy.
• Guideline status: Although mechanistically coherent, routine genetic testing of DIO1 to direct therapy is not yet recommended by major clinical guidelines due to a lack of large, prospective, genotype-stratified randomized controlled trials.

Bottom line

• Bottom line: The DIO1 rs2235544 polymorphism significantly shapes peripheral T3 production and LT4 dosing requirements. While evaluating this gene is highly valuable for explaining poor T4-to-T3 conversion—especially the low-activity AA genotype in patients with suboptimal fT3—its use in guiding T4/T3 combination therapy remains an emerging, investigational clinical tool.